Grepafloxacin - a new fluoroquinolone
Grepafloxacin is a new antibiotic drug in the class of fluoroquinolones. Marketed as Raxar, grepafloxacin is indicated for community-acquired pneumonia, bacterial chronic bronchitis, gonorrhea, urethritis and cervicitis. Grepafloxacin is effective against pneumococcal bacteria, including penicillin-resistant strains. In clinical trials, the drug was effective in once-daily dosing against a number of infections.
Publication Name: Medical Letter on Drugs and Therapeutics
Maimon M. Cohen: January 24, 1935, to January 25, 2007
Maimon Cohen was a leader in the field of human genetics and played an important role in its growth and development. In the year 1998, he became the first director of the Harvey Institute for Human Genetics at the Greater Baltimore Medical Centre where he developed a highly respected cytogenetic service laboratory.
Publication Name: American Journal of Human Genetics
Subject: Biological sciences
2006 model year deflating, but not yet a bust
The boat sales in United States are lagging due to various reasons starting from increased fuel prices. The impact of these high prices on boating industry and the future scope for improving situations is presented.
Publication Name: Soundings Trade Only
Subject: Construction and materials industries
- Abstracts: Balancing act. 5 new rules for buying a house. What ever happened to sideline sportsmanship?
- Abstracts: Intravenous ciprofloxacin. Intravenous amiodarone. Intravenous leiomyomatosis with cardiac extension: successful surgical management and histopathologic study
- Abstracts: Jumping to the wrong conclusion. Venus: Earth's ugly sister
- Abstracts: Trust in the future. Symbiotic arrangements as a challenge to antitrust
- Abstracts: How to recover when you've lost it. Mail campaign for soars for Eagle Crest